Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Bioavailability of Relugolix in Healthy Men
NCT02252354Phase 1Completed
- Sponsor
- Takeda
- Start
- Sep 2014
- Primary completion
- Oct 2014
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, open-label trial of relugolix in prostate cancer (PCa) (2 arms), sponsored by Takeda. Primary endpoints: Time to Reach the Maximum Plasma and Whole Blood Radioactivity Concentration (Cmax) for [14C]-TAK-385, Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-385 and 13 more. Started Sep 2014; status: completed.
02
Drugs
relugolix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02252354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02252354.